期刊
PROGRESS IN CARDIOVASCULAR DISEASES
卷 52, 期 4, 页码 326-335出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.pcad.2009.11.002
关键词
Anderson-Fabry disease; Cardiac hypertrophy; Arrhythmias; Enzyme replacement therapy
Anderson-Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations of the GLA gene that encodes alpha-galactosidase A. The ensuing enzyme deficiency results in intracellular accumulation of neutral glycosphingolipids (primarily globotriaosylceramide) and progressive renal, cardiac, and cerebrovascular disease. Female carriers are at risk of developing disease, but this tends to be milder and more slowly progressive than in males. Left ventricular hypertrophy is the most common cardiac manifestation followed by conduction system disease, valve dysfunction, and arrhythmias. Management of cardiovascular symptoms and the prevention of complications rely on conventional pharmacologic and device-based therapies, but data on the effect of enzyme replacement therapy suggest that it has the potential to attenuate and possibly reverse some aspects of cardiac involvement. (Prog Cardiovasc Dis 2010;52:326-335) (C) 2010 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据